دورية أكاديمية
IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma
العنوان: | IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma |
---|---|
المؤلفون: | Mimma Rizzo, Luca Varnier, Gaetano Pezzicoli, Marta Pirovano, Laura Cosmai, Camillo Porta |
المصدر: | Frontiers in Oncology, Vol 12 (2022) |
بيانات النشر: | Frontiers Media S.A., 2022. |
سنة النشر: | 2022 |
المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
مصطلحات موضوعية: | IL-8, biomarker of resistance, anti-angiogenic agent, immune checkpoint inhibitors, kidney cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
الوصف: | The therapeutic armamentarium of metastatic Renal Cell Carcinoma (mRCC) has consistently expanded in recent years, with the introduction of VEGF/VEGFR (Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor) inhibitors, mTOR (mammalian Target Of Rapamycin) inhibitors and Immune Checkpoint (IC) inhibitors. Currently, for the first-tline treatment of mRCC it is possible to choose between a VEGFR-TKI (VEGFR-Tyrosine Kinase Inhibitor) monotherapy, an ICI-ICI (Immune Checkpoint Inhibitor) combination and an ICI-VEGFRTKI combination. However, a consistent part of patients does not derive benefit from first-line therapy with ICIs; moreover, the use of combination regimens exposes patients to significant toxicities. Therefore, there is a critical need to develop prognostic and predictive biomarkers of response to VEGFR-TKIs and ICIs, and measurement of serum IL-8 is emerging as a potential candidate in this field. Recent retrospective analyses of large phase II and phase III trials found that elevated baseline serum IL-8 correlated with higher levels of tumor and circulating immunosuppressive myeloid cells, decreased T cell activation and poor response to treatment. These findings must be confirmed in prospective clinical trials; however, they provide evidence for a potential use of serum IL-8 as biomarker of resistance to VEGFR-TKIs and ICIs. Considering the amount of new agents and treatment regimens which are transforming the management of metastatic renal cell carcinoma, serum IL-8 could become a precious resource in tailoring the best therapy for each individual patient with the disease. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 2234-943X |
Relation: | https://www.frontiersin.org/articles/10.3389/fonc.2022.990568/full; https://doaj.org/toc/2234-943X |
DOI: | 10.3389/fonc.2022.990568 |
URL الوصول: | https://doaj.org/article/eeef596200f6422c87d1506e13f5b681 |
رقم الأكسشن: | edsdoj.f596200f6422c87d1506e13f5b681 |
قاعدة البيانات: | Directory of Open Access Journals |
كن أول من يترك تعليقا!